<DOC>
	<DOCNO>NCT00077597</DOCNO>
	<brief_summary>This study ass efficacy safety Mircera give intravenously treatment renal anemia chronic kidney disease patient dialysis currently receive epoetin erythropoietic substance . The anticipated time study treatment 1-2 year target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Mircera Treatment Anemia Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient &gt; =18 year age ; chronic renal anemia ; dialysis therapy least 2 week screen . woman pregnant , breastfeed use unreliable birth control method ; administration investigational drug within 4 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>